The early 1990s: The door opens...
HCV Ab makes diagnosis possible.
First meta-analysis of RCTs published in early 1991.
Epidemiologic and natural history data begin to emerge.
February, 1991: FDA approves IFN alfa-2b for treatment of chronic HCV (3MU TIW for 6 months).
Placebo-controlled trials end.